With respect to cytogenetics risk stratification according to NCCN guideline of AML, AML patients with favorable cytogenetics risk had significantly lower expression of TNFAIP2 than those with intermediate and unfavorable cytogenetics risk (P = 0.001. Here, TNFAIP2 is linked to acute myeloid leukemia.